Effect of Collavant® n2 in Healthy Male Adults With Exercise-induced Joint Discomfort.
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Native type II collagen (Collavant® n2), Placebo.
- Who it may be relevant to
- Registry conditions: Healthy Adult Male. Basic parameters: 40 years — 65 years · Male.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Spain
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Randomized, Double-blind, Placebo-controlled Clinical Study to Assess the Effect of Collavant® n2 on Joint Function and Performance in Healthy, Active Male Adults With Exercise-induced Joint Discomfort.
Overview
The present clinical study has been designed to evaluate the effect of Collavant® n2 at a daily dose of 40 mg on joint function and performance in healthy, amateur male runners with exercise-induced knee discomfort.
Detailed description
The COLLMOTION study is a randomized, double-blind, placebo-controlled, parallel clinical study designed to evaluate the effects of Collavant® n2 on joint function, performance and discomfort in healthy, physically active male adults experiencing exercise-induced knee discomfort.
A total of 80 healthy male amateur runners aged 40 to 65 years are enrolled and randomized in a 1:1 ratio to receive either Collavant® n2 (40 mg/day) or placebo for a total intervention period of 24 weeks. Eligible participants are required to train regularly (≥150 minutes per week), report persistent exercise-related knee discomfort, and meet predefined inclusion and exclusion criteria to ensure the absence of diagnosed knee pathology such as osteoarthritis.
The primary objective of the study is to assess differences from baseline and versus placebo in joint discomfort. Secondary objectives include the evaluation of joint function, physical performance, perceived exertion, pain intensity before exercise, time to pain recovery, and joint inflammation.
Safety and tolerability are evaluated throughout the study via monitoring of adverse events, vital signs, physical examinations, laboratory parameters, and quality-of-life assessments. Participants undergo assessments at baseline, 12 weeks, and 24 weeks.
Interventions
- Dietary supplement Native type II collagen (Collavant® n2)
Native type II collagen (Collavant® n2). 1 capsule 40 mg / day - Other Placebo
Placebo. 1 capsule / day
Primary outcome measures
- Change in Exercise-Induced Knee Joint Discomfort [Time frame: Baseline (week 0) to week 24]
Secondary outcome measures (8)
- Change in joint pain intensity after physical activity [Time frame: Baseline (week 0) to week 12]
- Change in joint pain intensity before physical activity [Time frame: Baseline (week 0) to week 12, baseline (week 0) to week 24]
- Time to recovery of knee pain after exercise [Time frame: Baseline (week 0) to week 12, baseline (week 0) to week 24]
- Change in physical performance during the running test [Time frame: Baseline (week 0) to week 12, baseline (week 0) to week 24]
- Change in perceived exertion during physical activity [Time frame: Baseline (week 0) to week 12, baseline (week 0) to week 24]
- Change in knee joint function [Time frame: Baseline (week 0) to week 12, baseline (week 0) to week 24]
- Change in knee joint inflammation [Time frame: Baseline (week 0) to week 12, baseline (week 0) to week 24]
- Change in cartilage biomarkers [Time frame: Baseline (week 0) to week 12, baseline (week 0) to week 24]
Eligibility criteria
Inclusion criteria
- Healthy physically active male adults (amateur runners) with exercise-induced joint discomfort, aged between 40 and 65 years
- Activity level: Amateur runners who train regularly a minimum of 150 minutes per week, divided into 2 or more sessions per week during at least 3 months. Principally, subjects training for popular running events of 10 Kms.
- Joint discomfort after activity: Self-reports target knee discomfort after training by a score of at least 20 mm VAS at screening. Discomfort persistent for at least 2w.
- Be willing to refrain from starting any new dietary supplements during the entire study that have any underlying joint benefits (collagen, glucosamine, chondroitin, MSM, Hyaluronic Acid, Turmeric, Natural Eggshell Membrane, Omega-3 fatty acids, PEA, Boswellia,..). If any of these supplements (except collagen) or any other dietary supplement has been taken consistently for at least 6 months prior to enrollment, participants should maintain the same stable intake pattern throughout the 24 week study period.
- Have individual devices to monitor training with GPS
- Sign informed consent
Exclusion criteria
- Diagnostic of knee osteoarthritis or any pathology or surgical intervention associated with the knee.
- Hypersensitivity to any component of the supplement or the placebo
- Chronic treatment with analgesic or anti-inflammatory (NSAIDs and corticosteroids families) drugs
- Treatment with any type of collagen supplement
- Treatment with probiotics or antibiotics
- Inability to train for the next 24 weeks
- Follow a vegan diet
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Other
Study locations
Spain · 1 center
- Universidad Politecnica de Madrid — Madrid
Identifiers
NCT: NCT07561203 · PJ-00186 / COLLMOTION · PJ-00186 / COLLMOTION